Mental and Substance Use Disorders Prevalence Study: Background and Methods

Objective The Mental and Substance Use Disorders Prevalence Study (MDPS) builds upon previous epidemiologic studies to provide estimates of prevalence and treatment rates of mental and substance use disorders among adults aged 18–65 in the U.S. The study background and methods are described. Method...

Full description

Saved in:
Bibliographic Details
Published in:International journal of methods in psychiatric research 2024-03, Vol.33 (1), p.n/a
Main Authors: Guyer, Heidi, Ringeisen, Heather, Dever, Jill, Liao, Dan, Peytchev, Andy, Carr, Christine, Geiger, Paul, Stambaugh, Leyla, Smith, Tim, Dixon, Lisa, Olfson, Mark, First, Michael, Stroup, Scott, Chwastiak, Lydia, Monroe‐Devita, Maria, Swanson, Jeff, Swartz, Marvin, Kessler, Ronald C., Gibbons, Robert, Bareis, Natalie, Sinclair Hancq, Elizabeth, Clarke, Thomas, Edlund, Mark, Smith, Thomas, Tennison, Mackenzie, Winans, Katherine, Graupensperger, Scott, Robertson, Allison
Format: Article
Language:English
Subjects:
clinical interview
epidemiologic research design
Original
prevalence
psychiatric epidemiology
SCID‐5
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective The Mental and Substance Use Disorders Prevalence Study (MDPS) builds upon previous epidemiologic studies to provide estimates of prevalence and treatment rates of mental and substance use disorders among adults aged 18–65 in the U.S. The study background and methods are described. Method The MDPS employed novel techniques such as the inclusion of household, prison, homeless and state psychiatric hospital populations, a semi‐structured clinical interview administered by trained clinical interviewers to assess disorders, the assessment of both past year and lifetime schizophrenia spectrum disorder (SSD) using full Diagnostic and Statistical Manual 5 criteria, as well as other mental and substance use disorders, and video‐based interviewing. Population specific and combined sample weights were developed to estimate nationally representative prevalence and treatment rates. Results Data collection was conducted between October 2020 and October 2022 resulting in 5679 clinical interviews. The statistical weighting and analytic plan are described. Weighted response rates and reasons for non‐response are provided for each study population. Conclusions The MDPS successfully developed and employed novel techniques to estimate the prevalence and treatment rates of mental and substance use disorders in both household and non‐household populations, including some of the most impairing disorders such as SSD.
ISSN:1049-8931
1557-0657
DOI:10.1002/mpr.2000